Millendo Therapeutics Stock

MLND

US60040X1037

Biotechnology & Medical Research

Latest news: Millendo Therapeutics

11/05/23	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
30/12/22	Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement	CI
01/10/21	Millendo Therapeutics, Inc. Joins Nicholas Maestas as Vice President, Strategy and Finance and It's Principal Financial Officer	CI
25/06/21	Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from NASDAQ Composite Index	CI
25/06/21	Tempest Therapeutics Inc. completed the acquisition of Millendo Therapeutics, Inc. in a reverse merger transaction for approximately $180 million.	CI
23/06/21	Millendo Therapeutics : , Tempest Therapeutics Investors Approve Merger Proposals	MT
13/05/21	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
29/03/21	Millendo Therapeutics, Inc., Tempest Therapeutics Inc. - M&A Call
29/03/21	Millendo Therapeutics : Tempest, Millendo Agree to Merge, Combined Company to List on NASDAQ	MT
29/03/21	Millendo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
29/03/21	Tempest Therapeutics Inc. entered into a definitive agreement and plan of merger to acquire Millendo Therapeutics, Inc. in a reverse merger transaction.	CI
29/01/21	Millendo Therapeutics, Inc. Announces Executive Changes	CI
29/01/21	Millendo Therapeutics, Inc. Plans to Reduce Its Workforce with Majority of Reduction in Personnel Expects to Complete by April 15, 2021	CI

More news

Analysts' recommendations: Millendo Therapeutics

07/01/21	Millendo Therapeutics : Ladenburg Thalmann Downgrades Millendo Therapeutics to Neutral from Buy	MT
07/01/21	Millendo Therapeutics : SVB Leerink Downgrades Millendo Therapeutics to Market Perform From Outperform; Price Target is $2	MT
10/11/20	Millendo Therapeutics : Wedbush Adjusts Price Target for Millendo Therapeutics to $2 From $3, Maintains Neutral Rating	MT

More recommendations

Press Releases: Millendo Therapeutics

24/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
17/07/21	Tempest Therapeutics : BUSINESS (Form 8-K)	PU
17/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/07/21	Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference	AQ
12/07/21	TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ

More press releases

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MILLENDO THERAPEUTICS	-14.88%	+3.21%	-	-	303M
WUXI APPTEC CO., LTD.	-1.06%	-0.07%	+60.76%	+68.61%	68.32B
ARGENX SE	+1.30%	+7.41%	+14.79%	+92.69%	60.26B
LONZA GROUP AG	+0.39%	+0.30%	+20.04%	+98.33%	55.86B
BEONE MEDICINES AG	-0.95%	+11.17%	+22.21%	+110.93%	48.43B
IQVIA HOLDINGS INC.	-0.23%	+4.07%	+25.63%	+40.08%	45.34B
REVOLUTION MEDICINES, INC.	-6.40%	-9.51%	+181.99%	+816.79%	41.76B
CELLTRION, INC.	+1.97%	+3.50%	+25.78%	+50.98%	34.5B
GENMAB A/S	-0.56%	-0.48%	+85.57%	+65.40%	33.8B
INSMED INCORPORATED	+1.05%	+9.77%	-37.66%	+408.42%	26.21B
Average	-1.94%	+1.46%	+44.35%	+194.69%	46B
Weighted average by Cap.	-0.54%	+1.44%	+45.34%	+173.07%

See all sector performances

Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.

Employees

Sector

Biotechnology & Medical Research

More about the company